Thrombopoietin-receptor agonists in haematological disorders: The Danish experience

References

• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–186
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386–2393
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133: 364–374
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909–913
   PubMed Web of Science ®Google Scholar
• Solberg LA, Jr. Biologic aspects of thrombopoietins and the development of therapeutic agents. Curr Hematol Rep 2005; 4: 423–428
   PubMedGoogle Scholar
• Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237–2247
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008; 371: 395–403
   PubMed Web of Science ®Google Scholar
• Frampton JE, Lyseng-Williamson KA. Romiplostim. Drugs 2009; 69: 307–317
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641–648
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009; 69: 567–576
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161–2171
   PubMed Web of Science ®Google Scholar
• Saleh MN, Cheng G, Bussel JB, Sun H, Mayer B, Bailey CK, Brainsky A, EXTEND Study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood 2010;116:Suppl:36–36
   Google Scholar
• Olen O, Montgomery SM, Elinder G, Ekbom A, Ludvigsson JF. Increased risk of immune thrombocytopenic purpura among inpatients with celiac disease. Scand J Gastroenterol 2008; 43: 416–422
   PubMed Web of Science ®Google Scholar
• Altintas A, Pasa S, Cil T, Bayan K, Gokalp D, Ayyildiz O. Thyroid and celiac diseases autoantibodies in patients with adult chronic idiopathic thrombocytopenic purpura. Platelets 2008; 19: 252–257
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227–2236
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28: 437–444
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117: 992–1000
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116: 3163–3170
   PubMed Web of Science ®Google Scholar
• Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa KY. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010; 26: 2339–2346
   PubMed Web of Science ®Google Scholar
• Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010; 24: 1096–1098
   PubMed Web of Science ®Google Scholar
• Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer 2010; 54: 490–491
   PubMed Web of Science ®Google Scholar
• Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116: 5832–5837
   PubMed Web of Science ®Google Scholar
• http://www.nplatehcp.com/safety-information.html
   Google Scholar
• Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: An indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139: 265–268
   PubMed Web of Science ®Google Scholar